Systems Biology Approaches for the Improvement of Oncolytic Virus-Based Immunotherapies
Cancers · 17.02.2023 · 15 (4) · 1297
DOI: 10.3390/cancers15041297 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 17.02.2023. Verfasst von Lorella Tripodi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università degli Studi di Napoli Federico II, 80138 Naples, Italy. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 125 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Research Council under the European Union’s Horizon 2020 Framework program, the Helsinki Institute of Life Science (HiLIFE), the Jane and Aatos Erkko Foundation.
Abstract (Originalsprache)
Oncolytic virus (OV)-based immunotherapy is mainly dependent on establishing an efficient cell-mediated antitumor immunity. OV-mediated antitumor immunity elicits a renewed antitumor reactivity, stimulating a T-cell response against tumor-associated antigens (TAAs) and recruiting natural killer cells within the tumor microenvironment (TME). Despite the fact that OVs are unspecific cancer vaccine platforms, to further enhance antitumor immunity, it is crucial to identify the potentially immunogenic T-cell restricted TAAs, the main key orchestrators in evoking a specific and durable cytotoxic T-cell response. Today, innovative approaches derived from systems biology are exploited to improve target discovery in several types of cancer and to identify the MHC-I and II restricted peptide repertoire recognized by T-cells. Using specific computation pipelines, it is possible to select the best tumor peptide candidates that can be efficiently vectorized and delivered by numerous OV-based platforms, in order to reinforce anticancer immune responses. Beyond the identification of TAAs, system biology can also support the engineering of OVs with improved oncotropism to reduce toxicity and maintain a sufficient portion of the wild-type virus virulence. Finally, these technologies can also pave the way towards a more rational design of armed OVs where a transgene of interest can be delivered to TME to develop an intratumoral gene therapy to enhance specific immune stimuli.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università degli Studi di Napoli Federico II, 80138 Naples, Italy.
- CEINGE Biotecnologie Avanzate Franco Salvatore, 80131 Naples, Italy.
- Laboratory of Immunovirotherapy, Drug Research Program, Faculty of Pharmacy, University of Helsinki, 00100 Helsinki, Finland.
- Translational Immunology Research Program (TRIMM), University of Helsinki, 00100 Helsinki, Finland.
- iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, 00100 Helsinki, Finland.
- Nouscom Srl, via Castel Romano 100, 00128 Rome, Italy.
ORCID-Profile: Lorella Tripodi, Emanuele Sasso, Sara Feola, Ludovica Coluccino, Maria Vitale, Lucio Pastore, Vincenzo Cerullo
Förderung
- European Research Council under the European Union’s Horizon 2020 Framework program
- the Helsinki Institute of Life Science (HiLIFE)
- the Jane and Aatos Erkko Foundation
- the Cancer Society of Finland (Syöpäjärjestöt)
- POR Campania FESR 2014/2020
Zitieren
APA
Tripodi, L., Sasso, E., Feola, S., Coluccino, L., Vitale, M., Leoni, G., Szomolay, B., Pastore, L., & Cerullo, V. (2023). Systems Biology Approaches for the Improvement of Oncolytic Virus-Based Immunotherapies. Cancers, 15(4), 1297. https://doi.org/10.3390/cancers15041297
Vancouver
Tripodi L, Sasso E, Feola S, Coluccino L, Vitale M, Leoni G, et al. Systems Biology Approaches for the Improvement of Oncolytic Virus-Based Immunotherapies. Cancers. 2023;15(4):1297. doi:10.3390/cancers15041297
BibTeX
@article{Tripodi2023,
author = {Tripodi, Lorella and Sasso, Emanuele and Feola, Sara and Coluccino, Ludovica and Vitale, Maria and Leoni, Guido and Szomolay, Barbara and Pastore, Lucio and Cerullo, Vincenzo},
title = {Systems Biology Approaches for the Improvement of Oncolytic Virus-Based Immunotherapies},
journal = {Cancers},
year = {2023},
volume = {15},
number = {4},
pages = {1297},
doi = {10.3390/cancers15041297}
}
EUVIMED